ベンダー
English

What exactly to make of PCR 'doubling' assets to $250B in an eye-blink...

Create a vendor selection project & run comparison reports
Click to express your interest in this report
Indication of coverage against your requirements
A subscription is required to activate this feature. Contact us for more info.
Celent have reviewed this profile and believe it to be accurate.
2018/03/13

Will Trout: I find it hard to believe that PCR could attempt to replicate Addepar's attempts to map and aggregate the entire investments ecosystem. I'm skeptical of Addepar's progress already

詳細はこちら

記事 details

Industry
Wealth Management
Media Type
Newsletters
Geographic Focus
Asia-Pacific, EMEA, LATAM, North America